



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Masanobu Kobayashi et al. Art Unit : 1641
Serial No. : 10/551,866 Examiner : Unknown
Filed : October 3, 2005
Title : PHARMACEUTICAL AGENTS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

The following correspondence relating to this application is enclosed for filing:

1. Information Disclosure Statement (1 page);
2. Form PTO-1449 (1 page);
3. Copies of cited references (16 references);
4. Copy of International Search Report (6 pages); and
5. A return postcard.

Please date stamp and return the enclosed postcard. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,




M. Angela Parsons, Ph.D.
Reg. No. 44,282

Date: June 13, 2006
Fish & Richardson P.C.
60 South Sixth Street, Suite 3300
Minneapolis, MN 55402
(612) 335-5070 telephone
(612) 288-9696 facsimile

60362539.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit June 13, 2006
Signature 
Typed or Printed Name of Person Signing Certificate Lisa M. Becker



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Masanobu Kobayashi et al.
 Serial No. : 10/551,866
 Filed : October 3, 2005
 Title : PHARMACEUTICAL AGENTS

Art Unit : 1641
 Examiner : Unknown

MAIL STOP AMENDMENT
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. §1.98(a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. A copy of a communication from a foreign patent office in a counterpart application is also enclosed. Please note that the reference Desig. ID No. AN is a Japanese document. Please refer to the enclosed International Search Report for an explanation of relevance.

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: June 13, 2006


M. Angela Parsons
 M. Angela Parsons, Ph.D.
 Reg. No. 44,282

Fish & Richardson P.C.
 60 South Sixth Street, Suite 3300
 Minneapolis, MN 55402
 Telephone: (612) 335-5070
 Facsimile: (612) 288-9696

60362292.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

June 13, 2006

Date of Deposit



Signature

Lisa M. Becker

Typed or Printed Name of Person Signing Certificate



Substitute Form PTO-1449 (Modified 4-2001)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18220-003US1	Application No. 10/551,866
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Masanobu Kobayashi et al.	
		Filing Date October 3, 2005	Group Art Unit 1641

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AB	Brown, "Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies," <u>Mol. Med. Today</u> , 2000, 61:157-162
	AC	Brown and Giaccia, "The Unique Physiology of Solid Tumors: Opportunities (and Problems) for Cancer Therapy," <u>Cancer Res.</u> , 1998, 58:1408-1416
	AD	Comerford et al., "Hypoxia-inducible Factor-1-dependent Regulation of the Multidrug Resistance (MDR1) Gene," <u>Cancer Res.</u> , 2002, 62:3387-3394
	AE	Cuypers et al., "Murine Leukemia Virus-Induced T-Cell Lymphomagenesis: Integration of Proviruses in a Distinct Chromosomal Region," <u>Cell</u> , 1984, 37:141-150
	AF	Dhanasekaran et al., "Delineation of prognostic biomarkers in prostate cancer," <u>Nature</u> , 2001, 412:822-826
	AG	Luk et al., "Effect of Transient Hypoxia on Sensitivity to Doxorubicin in Human and Murine Cell Lines," <u>J. Natl. Cancer Inst.</u> , 1990, 82:684-692
	AH	Möröy et al., "Expression of a <i>Pim-1</i> transgene accelerates lymphoproliferation and inhibits apoptosis in <i>lpr/lpr</i> mice," <u>Proc. Natl. Acad. Sci. USA</u> , 1993, 90:10734-10738
	AI	Niizeki et al., "Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells," <u>Br. J. Cancer</u> , 2002, 86:1914-1919
	AJ	Sakata et al., "Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance," <u>Br. J. Cancer</u> , 1991, 64:809-814
	AK	Sanna and Rofstad, "Hypoxia-Induced Resistance to Doxorubicin and Methotrexate in Human Melanoma Cell Lines <i>In Vitro</i> ," <u>Int. J. Cancer</u> , 1994, 58:258-262
	AL	Selten et al., "Proviral activation of the putative oncogene <i>Pim-1</i> in MuLV induced T-cell lymphomas," <u>EMBO J.</u> , 1985, 4(7):1793-1798
	AM	Teh, "Pim-1 induced by hypoxia is involved in drug resistance and tumorigenesis of solid tumor cells," <u>Hokkaido Igaku Zasshi</u> , 2004, 79:19-23, 25-26
	AN	Teicher, "Hypoxia and drug resistance," <u>Cancer Metastasis Rev.</u> , 1994, 13:139-168
	AO	Verbeek et al., "Mice Bearing the $\text{E}\mu\text{-}myc$ and $\text{E}\mu\text{-}pim-1$ Transgenes Develop Pre-B-Cell Leukemia Prenatally," <u>Mol. Cell. Biol.</u> , 1991, 11(2):1176-1179
	AP	Wang et al., "Pim-1: A serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis," <u>J. Vet. Sci.</u> , 2001, 2(3):167-179
	AQ	Zakut-Houri et al., "The cDNA sequence and gene analysis of the human <i>pim</i> oncogene," <u>Gene</u> , 1987, 54:105-111

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	